Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cross-Talk Between Non-Coding Rnas and Pi3k/Akt/Mtor Pathway in Colorectal Cancer Publisher Pubmed



Moafian Z1 ; Maghrouni A2 ; Soltani A3 ; Hashemy SI3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Molecular Biology Reports Published:2021


Abstract

Colorectal cancer (CRC) is the third commonest cancer globally, with metastasis being the reason for cancer-associated mortality. Much is still unknown biochemically about CRC, and with current treatments that are not wholly effective over time, new therapeutics are urgently needed. Emerging evidence has shown the importance of non-coding RNAs such as lncRNAs and miRNAs functions in the development and progression of CRC. However, the exact underlying mechanism of these types of RNAs in CRC is still mostly unknown. PI3K/AKT/mTOR pathway contributes to many cellular processes, and dysregulation of this pathway frequently occurs in cancers. In this review, the authors have mostly focused on the significant non-coding RNAs regulators of the PI3K/AKT/mTOR pathway and their contribution to the development or inhibition of CRC and their potential as diagnostic or therapeutic targets in CRC treatment. © 2021, The Author(s), under exclusive licence to Springer Nature B.V.
Other Related Docs
12. Critical Roles of Long Noncoding Rnas in Breast Cancer, Journal of Cellular Physiology (2020)
14. Arsenic Trioxide Alters the Microrna Expression Profile of U87 Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry (2016)